Reviewer’s report

Title: Efficacy of different dose of dexmedetomidine combined with remifentanil in colonoscopy: A randomized controlled trial

Version: 0 Date: 25 May 2020

Reviewer's report:

This is a RCT on the efficacy of different dosages of DEX combined with Remifentanil for sedation in colonoscopy in adults.

I have some major concerns related to this paper related to the methodology and the primary outcomes used.

1- the authors do not clearly state a primary or secondary outcome. The combination of different dosages of DEX with remifentanil do not reflect the efficacy in terms of reduced adverse events. The authors should have clearly state if this was a safety effect study (in this case adverse events should have been stated as primary outcome) but also secondary outcomes should have been clearly stated
2- there is a confusion on the use of BIS as a surrogate for sedation scales. This is not acceptable when a sedation protocol is examined
3- I don't understand why DEX was not used as bolus first followed by continuous infusion while remifentanil was administered as bolus followed by continuous infusion. From a pharmacokinetic point of view this makes the protocol biased
4- while there is mention on physicians' satisfaction there is no mention on patients' experience. This is unacceptable.
5- DEX has a long off-time. There is no mention on the recovery time after sedation, ALDRETE Scores and time required to discharge patients from the recovery area.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

No

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

No

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I have no conflict of interest to be declared related to this paper

Reviewer Publication Consent. I agree for my report to be made available under an Open Access Creative Commons CC-BY License (http://creativecommons.org/licenses/by/4.0) if this manuscript is accepted for publication. Any comments that I do not wish to be included in the published report have been included as confidential comments to the editor, which will not be published. If you are not happy for us to publish this report, please contact the editorial office before completing the review. If you wish, you can include your name in your published report. Please note you must decide whether to include your name at the start of the process and confirm this decision whenever prompted. If you change your decision later, we will not be able to publish your name.
I agree to the terms of the CC-BY 4.0 license; please publish my name with my report.